Literature DB >> 12445244

Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas.

W G McCluggage1.   

Abstract

Uterine carcinosarcomas (malignant mixed mullerian tumors) are metaplastic carcinomas. Uterine carcinosarcomas (malignant mixed Mullerian tumors) have been traditionally regarded as a subtype of uterine sarcoma. Adjuvant oncological treatments have often been similar to those directed against high-grade uterine sarcomas such as leiomyosarcoma and undifferentiated uterine sarcoma. However, there is now convincing evidence that most uterine carcinosarcomas are monoclonal neoplasms and are in reality metaplastic carcinomas. Although aggressive, the behavior of uterine carcinosarcoma is more akin to that of high-grade endometrioid type endometrial adenocarcinoma and aggressive morphological subtypes of uterine carcinoma. The sarcomatous component is derived from the carcinomatous element which is the driving force. Although the designation carcinosarcoma is likely to remain, adjuvant treatments should probably be similar to those directed against aggressive high grade endometrial carcinomas. Prospective studies should be performed to ascertain whether such adjuvant therapies are more effective than traditional sarcoma based therapies in the treatment of these aggressive neoplasms.

Entities:  

Mesh:

Year:  2002        PMID: 12445244     DOI: 10.1046/j.1525-1438.2002.01151.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  54 in total

1.  T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.

Authors:  Roberta Nicoletti; Salvatore Lopez; Stefania Bellone; Emiliano Cocco; Carlton L Schwab; Jonathan D Black; Floriana Centritto; Liancheng Zhu; Elena Bonazzoli; Natalia Buza; Pei Hui; Delia Mezzanzanica; Silvana Canevari; Peter E Schwartz; Thomas J Rutherford; Alessandro D Santin
Journal:  Clin Exp Metastasis       Date:  2014-11-15       Impact factor: 5.150

2.  Malignant mixed Mullerian tumors.

Authors:  J Ruiz Tovar; M E Reguero Callejas; J I Arano Bermejo; L F Capote Armas; F González-Palacios Martínez; L Cabañas Navarro
Journal:  Clin Transl Oncol       Date:  2006-02       Impact factor: 3.405

3.  DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics.

Authors:  Felix K F Kommoss; Damian Stichel; Daniel Schrimpf; Mark Kriegsmann; Basile Tessier-Cloutier; Aline Talhouk; Jessica N McAlpine; Kenneth T E Chang; Dominik Sturm; Stefan M Pfister; Laura Romero-Pérez; Thomas Kirchner; Thomas G P Grünewald; Rolf Buslei; Hans-Peter Sinn; Gunhild Mechtersheimer; Peter Schirmacher; Dietmar Schmidt; Hans-Anton Lehr; Felix Sahm; David G Huntsman; C Blake Gilks; Friedrich Kommoss; Andreas von Deimling; Christian Koelsche
Journal:  J Cancer Res Clin Oncol       Date:  2019-11-25       Impact factor: 4.553

4.  Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma.

Authors:  Gloria S Huang; Lydia G Chiu; Juliana S Gebb; Marc J Gunter; Paniti Sukumvanich; Gary L Goldberg; Mark H Einstein
Journal:  Gynecol Oncol       Date:  2007-10-23       Impact factor: 5.482

5.  Expression and localization of E-cadherin and β-catenin in uterine carcinosarcoma.

Authors:  Izumi Nishimura; Yoshihiro Ohishi; Yoshinao Oda; Junji Kishimoto; Masafumi Yasunaga; Emi Okuma; Hiroaki Kobayashi; Norio Wake; Masazumi Tsuneyoshi
Journal:  Virchows Arch       Date:  2010-11-03       Impact factor: 4.064

Review 6.  My approach to the interpretation of endometrial biopsies and curettings.

Authors:  W G McCluggage
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

Review 7.  Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma.

Authors:  Khadra Galaal; Esther van der Heijden; Keith Godfrey; Raj Naik; Ali Kucukmetin; Andrew Bryant; Nagindra Das; Alberto D Lopes
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

8.  Molecular classification and subtype-specific drug sensitivity research of uterine carcinosarcoma under multi-omics framework.

Authors:  Xiaofan Lu; Liya Zhang; Huiling Zhao; Chen Chen; Yaoyan Wang; Shengjie Liu; Xiao Lin; Yue Wang; Qianyuan Zhang; Tao Lu; Fangrong Yan
Journal:  Cancer Biol Ther       Date:  2018-10-25       Impact factor: 4.742

9.  A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.

Authors:  Aaron H Wolfson; Mark F Brady; Thomas Rocereto; Robert S Mannel; Yi-Chun Lee; Robert J Futoran; David E Cohn; Olga B Ioffe
Journal:  Gynecol Oncol       Date:  2007-09-05       Impact factor: 5.482

10.  Tissue microarray analysis of hormonal signaling pathways in uterine carcinosarcoma.

Authors:  Gloria S Huang; Rebecca C Arend; Maomi Li; Marc J Gunter; Lydia G Chiu; Susan Band Horwitz; Gary L Goldberg
Journal:  Am J Obstet Gynecol       Date:  2009-02-06       Impact factor: 8.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.